Mirum Pharmaceuticals, Inc. (MIRM)
Largest Insider Buys in Sector
MIRM Stock Price History Chart
MIRM Stock Performance
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, …
Insider Activity of Mirum Pharmaceuticals, Inc.
Over the last 12 months, insiders at Mirum Pharmaceuticals, Inc. have bought $115,064 and sold $1.92M worth of Mirum Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Mirum Pharmaceuticals, Inc. have bought $1.04M and sold $3.89M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BJERKHOLT ERIC (CHIEF FINANCIAL OFFICER) — $303,600. Heron Patrick J (director) — $110,912.
The last purchase of 115 shares for transaction amount of $4,301 was made by Heron Patrick J (director) on 2024‑09‑18.
List of Insider Buy and Sell Transactions, Mirum Pharmaceuticals, Inc.
| 2024-09-18 | director | 115 0.0002% | $37.40 | $4,301 | +3.75% | |||
| 2024-09-06 | director | 230 0.0005% | $41.58 | $9,563 | -4.17% | |||
| 2024-07-02 | Sale | SVP, GLOBAL CONTROLLER | 375 0.0008% | $34.00 | $12,750 | 0.00% | ||
| 2024-06-24 | Sale | CHIEF SCIENTIFIC OFFICER | 30,559 0.0633% | $34.00 | $1.04M | +14.59% | ||
| 2024-06-05 | Sale | director | 5,000 0.0104% | $25.68 | $128,400 | +50.23% | ||
| 2024-03-27 | CHIEF FINANCIAL OFFICER | 2,000 0.0042% | $24.80 | $49,600 | +43.86% | |||
| 2024-03-25 | Sale | PRESIDENT AND COO | 4,303 0.0091% | $25.80 | $111,017 | +30.00% | ||
| 2024-03-18 | CHIEF FINANCIAL OFFICER | 2,000 0.0043% | $25.80 | $51,600 | +26.24% | |||
| 2024-02-02 | Sale | CHIEF DEVELOPMENT OFFICER | 847 0.0018% | $26.19 | $22,184 | +7.20% | ||
| 2024-02-02 | Sale | CHIEF EXECUTIVE OFFICER | 6,013 0.0127% | $26.19 | $157,491 | +7.20% | ||
| 2024-02-02 | Sale | PRESIDENT AND COO | 1,790 0.0038% | $26.19 | $46,883 | +7.20% | ||
| 2024-02-02 | Sale | CHIEF SCIENTIFIC OFFICER | 1,214 0.0026% | $26.19 | $31,797 | +7.20% | ||
| 2024-02-02 | Sale | SVP, GLOBAL CONTROLLER | 735 0.0015% | $26.19 | $19,251 | +7.20% | ||
| 2024-01-08 | Sale | PRESIDENT AND CEO | 5,209 0.011% | $28.03 | $146,033 | -1.79% | ||
| 2024-01-08 | Sale | CHIEF DEVELOPMENT OFFICER | 1,019 0.0022% | $28.04 | $28,568 | -1.79% | ||
| 2024-01-08 | Sale | CHIEF OPERATING OFFICER | 1,408 0.003% | $28.03 | $39,473 | -1.79% | ||
| 2024-01-08 | Sale | HEAD OF RESEARCH & DEVELOPMENT | 1,408 0.003% | $28.03 | $39,472 | -1.79% | ||
| 2024-01-08 | Sale | SVP, GLOBAL CONTROLLER | 528 0.0011% | $28.04 | $14,803 | -1.79% | ||
| 2023-12-05 | Sale | SVP, Global Controller | 2,500 0.0053% | $32.40 | $81,000 | -12.95% | ||
| 2023-09-14 | Sale | director | 14,216 0.0367% | $32.00 | $454,912 | -11.63% |
Insider Historical Profitability
| Heron Patrick J | director | 162308 0.3402% | $41.16 | 7 | 0 | +5.09% |
| Longpre Lara | CHIEF DEVELOPMENT OFFICER | 104407 0.2188% | $41.16 | 1 | 5 | |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER | 104112 0.2182% | $41.16 | 4 | 5 | +41.16% |
| Vig Pamela | CHIEF SCIENTIFIC OFFICER | 27406 0.0574% | $41.16 | 1 | 6 | +53.04% |
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | 14000 0.0293% | $41.16 | 3 | 0 |
Institutional Investor Ownership
| Frazier Life Sciences Management L P | $163.16M | 13.78 | 6.5M | 0% | +$0 | 7.37 | |
| Bvf Inc Il | $109.78M | 9.27 | 4.37M | 0% | +$0 | 0.8 | |
| Eventide Asset Management | $82.91M | 7 | 3.3M | +23.91% | +$16M | 1.34 | |
| State Street | $70.9M | 5.99 | 2.82M | +62.7% | +$27.32M | <0.01 | |
| Janus Henderson | $69.47M | 5.87 | 2.77M | +34.16% | +$17.69M | 0.04 |